Today: 7 February 2026
Subscribe
Browse Category

Mergers and Acquisitions News 21 December 2025 - 7 January 2026

US stock market: Vistra stock pops in premarket on $4.7B Cogentrix deal amid AI power-demand boom

US stock market: Vistra stock pops in premarket on $4.7B Cogentrix deal amid AI power-demand boom

Vistra shares rose 4.4% to $170.17 premarket Tuesday after agreeing to buy Cogentrix Energy from Quantum Capital Group in a deal valued at $4.7 billion. The acquisition adds 5.5 gigawatts of natural gas generation across key U.S. markets and is expected to close in mid-to-late 2026. Vistra said the deal should boost per-share cash flow starting in 2027.
6 January 2026
···
BlueScope Steel stock jumps 21% on A$30 takeover bid — the next catalyst investors are watching

BlueScope Steel stock jumps 21% on A$30 takeover bid — the next catalyst investors are watching

BlueScope Steel shares jumped 20.6% to A$29.48 after SGH and Steel Dynamics made a non-binding A$30-per-share takeover offer. The proposal, received Dec. 12, is subject to due diligence, exclusivity, and other conditions. BlueScope’s board is reviewing the bid against its own valuation. The company previously rejected lower offers, citing execution risks.
6 January 2026
···
Uber stock slips as SpotHero acquisition-talk report emerges in year-end trade

Uber stock slips as SpotHero acquisition-talk report emerges in year-end trade

Uber shares slipped 0.3% to $81.87 after a report said the company has held talks to acquire parking app SpotHero, which was last valued at about $290 million. SpotHero operates in over 400 North American cities. Traders await confirmation of the talks and Uber’s next earnings report, expected Feb. 4. Lyft rose 0.2% while DoorDash fell 0.2% in afternoon trading.
31 December 2025
··
Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax’s U.S.-listed shares fell 3.8% to $133.04 late Wednesday morning, reversing part of a recent surge driven by takeover speculation and index inclusion. Trading volume reached about 348,000 shares as the stock swung between $132.13 and $140.25. Investors await updates on strategic interest and new data for obefazimod, the company’s lead drug candidate.
31 December 2025
··
Coforge’s $2.35 billion Encora deal tops India’s stocks-to-watch list for Dec. 29

Coforge’s $2.35 billion Encora deal tops India’s stocks-to-watch list for Dec. 29

NEW YORK, December 28, 2025, 22:48 ET Indian stocks were set for a firmer start on Monday, with IT services firm Coforge in focus after it agreed to buy U.S.-based Encora in a deal valued at $2.35 billion on an enterprise-value basis, according to Moneycontrol. GIFT Nifty futures rose 40 points to 26,100, Upstox reported. Moneycontrol+1 The deal lands in the final stretch of year-end trading, when big corporate announcements can drive sharp moves in individual shares even if broader volumes thin out. Investors also had fresh catalysts ranging from stake sales to regulatory filings and contract wins. Moneycontrol+2Moneycontrol+2 Coforge,
29 December 2025
··
Ondas Holdings (NASDAQ: ONDS) Stock News Today: Defense-Drone Contracts, M&A Momentum, and Fresh Analyst Targets in a Thin Holiday Market

Ondas Holdings (NASDAQ: ONDS) Stock News Today: Defense-Drone Contracts, M&A Momentum, and Fresh Analyst Targets in a Thin Holiday Market

As of 1:47 p.m. in New York on Friday, December 26, 2025, U.S. markets are open, but the tape is behaving like a post-holiday hallway: quieter than usual, with sudden echoes when a small-cap name trips an algorithm. Ondas Holdings Inc. (ONDS) is one of those echo-makers today. Shares are trading around $8.56, down roughly $0.57 (about -6%) on the session, after opening near $9.10 and printing an intraday range of about $8.55 to $9.18, with volume over 24 million shares. That downside move is happening against a mostly subdued broader market backdrop: large-cap ETFs are near flat-to-slightly-down (SPY), tech
26 December 2025
···
Zeta Global (ZETA) Stock Today: Marigold Deal, AI-Agent Momentum, and Wall Street Targets as Markets Reopen After Christmas

Zeta Global (ZETA) Stock Today: Marigold Deal, AI-Agent Momentum, and Wall Street Targets as Markets Reopen After Christmas

NEW YORK — Friday, December 26, 2025 (10:17 a.m. ET).Zeta Global Holdings Corp. (NYSE: ZETA) is trading around $19.12 in late-morning action, essentially flat on the day after opening near $19.05, with early trading ranging roughly between $18.70 and $19.20. Today’s tape has the familiar post-holiday feel: U.S. stocks opened mixed as traders returned from the Christmas break, and volumes were widely expected to be lighter into year-end. AP News Seasonality watchers also point out that Dec. 26 has historically been one of the strongest calendar days for U.S. equities, though history is not a trade plan. MarketWatch For Zeta
26 December 2025
···
AI Stocks Today (Dec. 25, 2025): Nvidia’s Groq Deal, Snowflake’s M&A Talks, UiPath’s Index Boost, and Meta’s WhatsApp AI Clash

AI Stocks Today (Dec. 25, 2025): Nvidia’s Groq Deal, Snowflake’s M&A Talks, UiPath’s Index Boost, and Meta’s WhatsApp AI Clash

December 25, 2025 — It’s Christmas Day, U.S. markets are taking a breather, and yet the AI-stock news cycle is doing what it always does: refusing to sleep. With investors digesting a holiday-thinned week of announcements, today’s biggest AI-stock narratives revolve around AI inference hardware, software consolidation, and regulatory pressure on AI distribution channels—the plumbing that decides which chatbots can reach billions of users. Below is what’s driving “AI stocks today” headlines on 25.12.2025, and why each item matters for 2026 positioning. Nvidia’s Groq licensing deal puts AI inference back in the spotlight The biggest AI-stock story dominating headlines into
25 December 2025
······
AI Stocks Today (Dec. 24, 2025, 5:02 p.m. ET): Nvidia’s Reported $20B Groq Deal, Snowflake M&A Talk, and Wall Street’s 2026 AI Outlook

AI Stocks Today (Dec. 24, 2025, 5:02 p.m. ET): Nvidia’s Reported $20B Groq Deal, Snowflake M&A Talk, and Wall Street’s 2026 AI Outlook

As of 5:02 p.m. ET on Wednesday, December 24, 2025, the “AI trade” is closing out a holiday-shortened session with fresh momentum — and a new set of questions investors can’t ignore. On one hand, U.S. benchmarks pushed to new records during the early Christmas Eve close, a classic “Santa rally” setup supported by easing-rate expectations and renewed appetite for mega-cap tech and AI names. On the other hand, today’s biggest AI headlines aren’t just about chips and models anymore. They’re increasingly about dealmaking, data-center financing, capital-expenditure transparency, and regulatory pressure on how AI assistants get distributed to consumers. Reuters+1
24 December 2025
··
Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Dynavax Technologies Corporation (NASDAQ: DVAX) is the center of the biotech tape on Wednesday, December 24, 2025, after Sanofi announced a deal to acquire the vaccine maker in an all-cash transaction valued at roughly $2.2 billion. The headline number investors are keying on: $15.50 per share in cash—a bid that reframes the near-term outlook for DVAX stock from “earnings and pipeline execution” to “deal timeline and closing risk.” Sanofi+1 Below is what’s driving today’s move, how the market is pricing the deal so far, what Wall Street forecasts looked like before the announcement, and the key dates and risks investors
24 December 2025
···
Clearwater Analytics (CWAN) Stock News on Dec. 23, 2025: $24.55 Take-Private Deal, Go‑Shop Window, Analyst Reactions, and What Investors Should Watch

Clearwater Analytics (CWAN) Stock News on Dec. 23, 2025: $24.55 Take-Private Deal, Go‑Shop Window, Analyst Reactions, and What Investors Should Watch

Clearwater Analytics Holdings, Inc. (NYSE: CWAN) is trading like a classic merger-arbitrage stock on December 23, 2025—hovering just below the agreed buyout price after the company signed a definitive deal to go private. Shares recently changed hands around $24.06, closely tracking the $24.55-per-share all-cash acquisition price. The tight gap reflects a market that is largely pricing in deal completion, while still attaching some risk to timing, approvals, and the possibility—however slim—of a higher bid emerging during the “go-shop” period. Below is a full, news-style breakdown of what’s happening with Clearwater Analytics stock, what the buyout terms actually say, what analysts
23 December 2025
·
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Analyst Downgrades, and What Investors Watch Next (Dec. 22, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Analyst Downgrades, and What Investors Watch Next (Dec. 22, 2025)

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is trading like a classic “deal stock” on December 22, 2025—hovering just below a fixed cash acquisition price after BioMarin Pharmaceutical (NASDAQ: BMRN) agreed to buy the company in an all-cash transaction. As of the latest available trade on Dec. 22, FOLD is around $14.22, with the market effectively pricing in the probability, timing, and risk of the merger closing—rather than the stand-alone upside of Amicus’ rare disease commercial portfolio. Below is a detailed roundup of the current news, forecasts, and analyst/market commentary shaping Amicus stock on 22.12.2025—and the specific catalysts that can still move
22 December 2025
··
ABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes EffectABIVAXABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes Effect

ABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes EffectABIVAXABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes Effect

PARIS / NEW YORK — December 22, 2025 — ABIVAX Société Anonyme (Abivax SA) stock is back in the spotlight on Monday after renewed takeover chatter tied to U.S. pharma giant Eli Lilly—arriving the same morning Abivax’s addition to the Nasdaq Biotechnology Index (NBI) becomes effective. The combination is fueling a sharp move in ABVX shares and re-igniting debate about whether 2025’s biotech breakout is now morphing into an M&A (mergers and acquisitions) story. What’s happening with ABIVAX stock today (December 22, 2025) Abivax shares rose sharply in Monday trading as media reports revived speculation that Eli Lilly could be
22 December 2025
·
ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

December 22, 2025 — ABIVAX Société Anonyme (ticker ABVX on Nasdaq and Euronext Paris) is back in the spotlight today, with traders juggling two storylines that can move a biotech stock fast: renewed takeover speculation involving Eli Lilly and Abivax’s addition to the Nasdaq Biotechnology Index (NBI), effective before today’s market open. GlobeNewswire+2Investing.com+2 In early market action, multiple outlets reported double‑digit gains in Abivax’s U.S. premarket trading and strong moves in Paris, making ABVX one of the morning’s most-watched biotech tickers. Benzinga+2Investing.com+2 But the bigger reason ABIVAX stock keeps showing up in “top movers” lists isn’t just rumor-driven volatility. The
22 December 2025
····
Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (NASDAQ: FOLD) is no longer trading like a “typical biotech story stock.” After BioMarin’s all-cash $14.50-per-share takeover agreement, FOLD has effectively become a deal-driven, merger-arbitrage name—meaning next week’s action is likely to hinge less on quarterly fundamentals and more on the probability, timing, and conditions of closing. SEC+1 FOLD last traded around $14.18 (near the offer price), reflecting how quickly the market repriced the shares after the announcement. Investors.com Below is the week-ahead playbook: the latest news as of 21.12.2025, what Wall Street is saying, and the specific catalysts that could
22 December 2025
····
ServiceNow (NOW) Stock Week Ahead: Armis Deal Chatter, Moveworks Integration, 5-for-1 Split Fallout, and Fresh Analyst Targets

ServiceNow (NOW) Stock Week Ahead: Armis Deal Chatter, Moveworks Integration, 5-for-1 Split Fallout, and Fresh Analyst Targets

ServiceNow, Inc. (NYSE: NOW) heads into the week of December 22–26, 2025 with momentum in its product narrative—but also with headline risk that has recently dominated the stock. The company has closed its largest acquisition to date (Moveworks), announced a security-focused buyout of identity specialist Veza, and completed a 5-for-1 stock split—all while markets digest reports that ServiceNow is in advanced talks to buy cybersecurity firm Armis for up to $7 billion. Reuters+3ServiceNow Newsroom+3ServiceNow Newsroom+3 With U.S. markets entering a holiday-shortened, potentially low-liquidity week—and with macro data still on the calendar—ServiceNow stock could be especially sensitive to incremental headlines, analyst
21 December 2025
··
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Latest News, Analyst Forecasts, and What Comes Next (Dec. 21, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Latest News, Analyst Forecasts, and What Comes Next (Dec. 21, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (Nasdaq: FOLD) has effectively become a “deal stock” — the market is now trading the shares primarily on the odds and timing of a takeover rather than on classic biotech catalysts. The reason is simple: on December 19, 2025, BioMarin Pharmaceutical announced a definitive agreement to acquire Amicus for $14.50 per share in cash, valuing Amicus at about $4.8 billion. SEC+1 With U.S. markets closed this weekend, the last meaningful read is Friday’s action: Market data services show Amicus closing around $14.20 on Dec. 19, with trading also widely reported near
21 December 2025
··
Amicus Therapeutics (FOLD) Stock Jumps on BioMarin’s $4.8B Buyout: Latest News, Forecasts, and Deal Analysis as of Dec. 20, 2025

Amicus Therapeutics (FOLD) Stock Jumps on BioMarin’s $4.8B Buyout: Latest News, Forecasts, and Deal Analysis as of Dec. 20, 2025

Amicus Therapeutics, Inc. (NASDAQ: FOLD) has become one of the most closely watched rare-disease stocks heading into the final stretch of 2025 after BioMarin Pharmaceutical announced a definitive agreement to acquire Amicus in an all-cash transaction valued at about $4.8 billion. The offer price—$14.50 per share in cash—instantly reset the “center of gravity” for FOLD shares and shifted investor focus from traditional biotech catalysts (quarterly launches, pipeline readouts, reimbursement updates) to merger timing, regulatory approvals, and closing risk. SEC+1 As of the latest available pricing around Dec. 20, 2025 (UTC), Amicus shares were trading around $14.18, after a sharp, deal-driven
21 December 2025
··
1 2 3 4 … 6

Stock Market Today

Palantir stock price rebounds after AI shakeout — what traders watch next week

Palantir stock price rebounds after AI shakeout — what traders watch next week

7 February 2026
New York, Feb 7, 2026, 14:34 ET — Market closed. Palantir Technologies Inc (PLTR) shares ended Friday up 4.5% at $135.90, closing out another uneven stretch for the AI-linked software name ahead of Monday’s reopening. (TradingView) The bounce came after Palantir’s latest results reset expectations earlier this week, with the company reporting a 70% jump in fourth-quarter revenue to $1.407 billion and pointing to 61% revenue growth in 2026, its earnings release showed. U.S. commercial revenue rose 137% and U.S. government revenue increased 66%. (Barchart.com) But the mood around pricey AI and software stocks has been jumpy. Palantir fell 6.8%
Coca-Cola stock price ends near $79 — frozen products exit sets up KO earnings week

Coca-Cola stock price ends near $79 — frozen products exit sets up KO earnings week

7 February 2026
Coca-Cola will discontinue its frozen products, including the Minute Maid frozen line, in the U.S. and Canada in Q1 2026. Shares closed Friday up 0.66% at $79.03 ahead of Tuesday’s quarterly results. CEO James Quincey sold 337,824 shares on Feb. 3 for about $26 million under a pre-arranged plan. Options pricing suggests a possible 3% move after earnings.
Cisco stock jumps 3% into earnings week as tech shakeout keeps CSCO in focus

Cisco stock jumps 3% into earnings week as tech shakeout keeps CSCO in focus

7 February 2026
Cisco shares closed up 3% at $84.82 Friday after a volatile week for tech stocks. The company will report quarterly results Feb. 11, with analysts expecting EPS of $1.02 on $15.12 billion revenue. U.S. jobs and inflation data, delayed by the federal shutdown, are also due next week. About 23.9 million Cisco shares traded Friday.
Go toTop